Research analysts at B. Riley assumed coverage on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) in a research note issued to investors on Thursday, Marketbeat.com reports. The firm set a “neutral” rating and a $3.50 price target on the biopharmaceutical company’s stock. B. Riley’s price objective indicates a potential upside of 20.69% from the company’s previous close.
Other equities research analysts also recently issued reports about the company. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Monday, November 6th. Leerink Swann restated a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a report on Monday, December 11th. Finally, BidaskClub upgraded Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, December 21st. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $4.89.
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded up $0.05 on Thursday, hitting $2.90. 3,208,078 shares of the stock were exchanged, compared to its average volume of 1,598,326. The stock has a market capitalization of $399.79, a price-to-earnings ratio of -6.04 and a beta of 1.32. Achillion Pharmaceuticals has a twelve month low of $2.58 and a twelve month high of $5.66.
Several institutional investors have recently bought and sold shares of ACHN. Teacher Retirement System of Texas purchased a new stake in shares of Achillion Pharmaceuticals in the fourth quarter valued at about $109,000. SG Americas Securities LLC raised its holdings in shares of Achillion Pharmaceuticals by 59.8% in the 3rd quarter. SG Americas Securities LLC now owns 42,229 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 15,800 shares during the period. Legal & General Group Plc raised its holdings in shares of Achillion Pharmaceuticals by 53.8% in the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 15,000 shares during the period. Bourgeon Capital Management LLC raised its holdings in shares of Achillion Pharmaceuticals by 64.4% in the 4th quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 19,004 shares during the period. Finally, Voya Investment Management LLC raised its holdings in shares of Achillion Pharmaceuticals by 13.7% in the 2nd quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 6,730 shares during the period. 76.78% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/11/achillion-pharmaceuticals-achn-research-coverage-started-at-b-riley.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.